ALUMIS
Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
ALUMIS
Industry:
Biotechnology Health Care Life Science
Founded:
2021-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.alumis.co
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
270 M USD
Technology used in webpage:
Google Apps For Business GoDaddy DNS Fastly Hosted Fastly Load Balancer
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
XinThera
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Current Advisors List
Current Employees Featured
Founder
Investors List
Matrix Capital Management
Matrix Capital Management investment in Series B - Alumis
Foresite Capital
Foresite Capital investment in Series A - Alumis
Key Employee Changes
Official Site Inspections
http://www.alumis.co Semrush global rank: 4.59 M Semrush visits lastest month: 1.22 K
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Alumis"
The leadership team and Board of Directors at Alumis Inc.
Leadership Team Our leaders are experienced drug developers who are committed to transforming the treatment paradigm for patients living with immune-mediated diseases. Our …See details»
Investor Relations | Alumis Inc.
Nov 4, 2024 Alumis Inc. Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.See details»
Alumis - LinkedIn
Alumis Biotechnology Research South San Francisco, California 4,957 followers Transforming the lives of patients living with immune-mediated diseases using a precision approach.See details»
Alumis - Crunchbase Company Profile & Funding
Where is Alumis's headquarters? Alumis is located in South San Francisco, California, United States. Who are Alumis's competitors? Alternatives and possible competitors to Alumis may include Context Therapeutics, BlueRock …See details»
Alumis Inc. (ALMS) Company Profile & Overview
Jun 28, 2024 Company profile for Alumis Inc. (ALMS) with a description, list of executives, contact details and other key facts.See details»
Our Approach at Alumis Inc.
Our Approach At Alumis, our driving principle is to deliver the right medicine to achieve the best possible clinical outcome. To realize that goal, we are using our precision approach to immunology focused on the important drivers of …See details»
Esker Therapeutics Announces Name Change to Alumis …
Jan 6, 2022 The company’s name change to Alumis (“alumer” for “lighten/enlightened” and “immunis” for “immunology”) is reflective of the transformation of the organization and overall vision ...See details»
Alumis - Crunchbase Company Profile & Funding
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.See details»
Esker Therapeutics Announces Name Change to Alumis and …
Jan 6, 2022 The company’s name change to Alumis (“alumer” for “lighten/enlightened” and “immunis” for “immunology”) is reflective of the transformation of the organization and overall …See details»
Alumis Expands Industry-Leading Leadership Team …
Apr 6, 2022 Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as Chief Financial Officer April 06, 2022 07:30 AM Eastern ...See details»
Alumis Company Profile 2024: Stock Performance & Earnings
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for …See details»
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
Jun 10, 2024 Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu The biotech aims to capitalize on rising interest in immune drug developers, a good number of which have been …See details»
Therapy developer Alumis seeks up to $1 bln valuation in US IPO
Jun 24, 2024 Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday.See details»
Alumis Inc. (ALMS) Stock Price, Quote & News - Stock Analysis
5 days ago Get a real-time Alumis Inc. (ALMS) stock price quote with breaking news, financials, statistics, charts and more.See details»
Why It Matters - Alumis
Why It Matters The harmful and broad impact of immune-mediated diseases requires a new approach to achieve better options that offer superior efficacy, safety and convenience. We …See details»
Alumis raises $250m in IPO as biotech stock stirs
Jun 28, 2024 Alumis raises $250m in IPO as biotech stock stirs Though downsized, Alumis still secured one of the largest IPOs within the biotech sector this year.See details»
Alumis' $100 Million IPO: Promising Psoriasis Treatment Results
Jun 11, 2024 Alumis' lead candidate ESK-001 shows positive trial results for psoriasis treatment. Read why ALMS stock will likely see substantial demand going forward.See details»
Careers, Values and Life at Alumis Inc.
Life at Alumis At Alumis we are driven by a deep dedication to transforming the lives of people suffering from immune-mediated diseases - we work hard to achieve this aspiration. We also …See details»
Alumis Company Profile - Office Locations, Competitors, Revenue ...
Oct 29, 2024 Alumis has 1 employees at their 1 location. See insights on Alumis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»